

SHELCAL M

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
Abbreviated Prescribing information for Shelcal M Tablets (Calcium carbonate, Vitamin D₃ and Minerals)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: *Calcium Carbonate:* Calcium is a mineral that is present naturally in the food *Vitamin D₃:* Cholecalciferol is the naturally occurring form of Vitamin D₃. It is produced from 7-dehydro cholesterol, a sterol present in mammalian skin, by ultraviolet irradiation.

INDICATION: It is used as a calcium and mineral supplement in deficiency states like during growth, pregnancy and lactation, prevention and treatment of osteoporosis.

DOSAGE AND ADMINISTRATION: One tablet twice daily or as directed by the physician.

CONTRAINDICATION: Shelcal M should not be given to patients with hypercalcaemia, bone metastases or other malignant bone disease, sarcoidosis, primary hyperparathyroidism, vitamin D overdose and severe renal failure or evidence of vitamin D toxicity. It is also contraindicated in the patients having hypersensitivity to any of the ingredients of Shelcal M.

WARNINGS & PRECAUTIONS: Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. In the patients with a history of renal stones urinary calcium excretion should be measured. With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function.

DRUG INTERACTIONS: Thiazide diuretics can reduce urinary calcium excretion. Hypercalcaemia must be avoided in digitalized patients. Concomitant treatment with phenytoin or barbiturates and glucocorticoids can decrease the effect of vitamin D. The effects of digitalis and other cardiac glycosides may accentuated with the oral administration of calcium combined with vitamin D. Calcium salts may reduce the absorption of thyroxine, bisphosphonates, sodium fluoride, quinolone or tetracycline antibiotics or iron.

ADVERSE REACTIONS: Abdominal pain, vomiting, flatulence, nausea, constipation, tachycardia, palpitation, hypercalciuria, hypersensitivity reaction.

MARKETED BY:

TORRENT
PHARMA

Torrent Pharmaceuticals Limited.

IN/SHELCAL M/Mar-2026/02/ABPI

(Additional information is available on request)